<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312462266</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312462266</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Therapeutic resistance in autoimmune diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Vasconcelos</surname><given-names>C</given-names></name>
<xref ref-type="corresp" rid="corresp1-0961203312462266"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Faria</surname><given-names>R</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-0961203312462266">Hospital Geral Santo Antonio, Largo Abel Salazar, Portugal</aff>
<author-notes>
<corresp id="corresp1-0961203312462266">Correspondence to: Carlos Vasconcelos, Hospital Geral Santo Antonio, Largo Abel Salazar, Porto, 4050, Portugal. Email: <email>cvcarlosvasconcelos@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>1</issue>
<fpage>3</fpage>
<lpage>5</lpage>
<history>
<date date-type="received"><day>21</day><month>8</month><year>2012</year></date>
<date date-type="accepted"><day>30</day><month>8</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>We are living in new times in medicine: New therapeutic strategies point to early intervention in many autoimmune diseases and, over time, frequent changes in drugs in the absence of response to clearly defined clinical and biological targets.</p>
<p>In addition, with the emergence of new drugs, better definitions are needed in trials in order to avoid misclassification as “therapeutic resistant” (TR).</p>
<p>But what really is TR in autoimmune diseases? Is it the same as refractory disease? What are the causes of TR? Can we prevent or overcome it?</p>
<p>TR means inefficacy of treatment. However, first it is important to clearly define the targets set with a specific treatment. Several other premises must also be confirmed before assuming it (<xref ref-type="table" rid="table1-0961203312462266">Table 1</xref>). Patient drug intolerability does not necessarily lead to a TR definition.
<table-wrap id="table1-0961203312462266" position="float"><label>Table 1</label><caption><p>Exclusion criteria for a therapeutic resistance (TR) definition</p></caption>
<graphic alternate-form-of="table1-0961203312462266" xlink:href="10.1177_0961203312462266-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Exclusion criteria for a therapeutic resistance (TR) definition.</th>
</tr></thead>
<tbody align="left">
<tr>
<td>If any answer is NO, TR definition cannot be applied.</td>
</tr>
<tr>
<td>1. Is there a correct definition of the therapeutic targets?</td>
</tr>
<tr>
<td>Is there a correct diagnosis and organ involvement?</td>
</tr>
<tr>
<td>Is damage excluded?</td>
</tr>
<tr>
<td>2. Is therapeutic compliance confirmed?</td>
</tr>
<tr>
<td>3. Are drug levels adequate?</td>
</tr>
<tr>
<td>4. Is there enough time on treatment?</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>When the therapeutic target is not achieved, the diagnosis should be revised and occult disease should be pursued. For example, a patient with cerebral small vessel thrombosis (personal experience) was diagnosed with antiphospholipid syndrome (APS) and continued to have cerebral thrombotic events and worsened migraine on adequate anticoagulation. The brain magnetic resonance imaging (MRI) and genetic test later confirmed cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) disease, and the small vessel disease was not due to APS. Another patient with pulmonary arterial hypertension related to anti-centromere scleroderma<sup><xref ref-type="bibr" rid="bibr1-0961203312462266">1</xref></sup> worsened with calcium antagonists because of occult pulmonary veno-occlusive disease. Another example is the over diagnosis of Evans Syndrome and its lack of response to classic treatment when the thrombocytopenia and autoimmune hemolytic anemia are from different causes.<sup><xref ref-type="bibr" rid="bibr2-0961203312462266">2</xref></sup></p>
<p>The efficacy of a treatment depends on adequate drug levels. And this depends on patient adherence to treatment, on the correct route of administration, on adequate absorption, on drug interactions and, often, a high inter-individual pharmacokinetic variability. Rates of non-compliance are known to range from 10% to 70% in systemic lupus erythematosus (SLE) for example,<sup><xref ref-type="bibr" rid="bibr3-0961203312462266">3</xref></sup> and drug level monitoring is not widely clinically available. Thus, patients thought to be resistant may have lower blood levels of a drug even when taking a high standard dose.<sup><xref ref-type="bibr" rid="bibr3-0961203312462266">3</xref></sup> For instance, Arnaud et al.<sup><xref ref-type="bibr" rid="bibr3-0961203312462266">3</xref></sup> showed a 10-fold variation in mycophenolate mofetil (MMF) levels in SLE patients per gram of MMF given and a marked underexposure in many. Another issue is the adjustment of dosage to extremes of weight. For example, one of our dermatomyositis patients did not deplete on rituximab 1 g two weeks apart, but later depleted and responded to the adjusted dosage to her 120 kg body weight (personal experience).</p>
<p>Another important point is the time to response. For instance, in lupus nephritis, less than 50% of the patients have a response in six months and some patients only at two years.<sup><xref ref-type="bibr" rid="bibr4-0961203312462266">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203312462266">5</xref></sup> So time to response is an essential variable to the definition of TR.</p>
<p>After defining the exclusion criteria to consider TR, we should explore the treatment response evaluation. Depending on the treatment aim, one can evaluate response globally/systemically or organ specifically. For each case it can range from complete or adequate response, to partial response and to complete absence of response.</p>
<p>What about “partial response”? Although there are definitions for partial response for several clinical settings, such as rheumatoid arthritis American College of Rheumatology (ACR) scores<sup><xref ref-type="bibr" rid="bibr6-0961203312462266">6</xref></sup> or response criteria for lupus nephritis,<sup><xref ref-type="bibr" rid="bibr7-0961203312462266">7</xref></sup> what do these mean for the acquisition of damage? In lupus nephritis we know that patients with partial response have a greater risk for chronic renal failure at 10 years.<sup><xref ref-type="bibr" rid="bibr8-0961203312462266">8</xref></sup></p>
<p>Absence of response to a given treatment can happen at the beginning of a specific treatment (primary failure) or after some time using the same treatment (secondary failure). Lack of response to tumor necrosis factor (TNF) inhibitors and rituximab in rheumatoid arthritis are probably the most studied clinical situations, and different mechanisms have been proposed for primary and secondary therapeutic failure.<sup><xref ref-type="bibr" rid="bibr9-0961203312462266">9</xref></sup> These are teaching us about possible different molecular and immunologic pathways of the disease and its behavior as syndromes rather than as single diseases. For example, there can be different stages in a disease for therapeutic intervention and different purposes, like induction, maintenance and at flare. Early versus late disease is a well-recognized concept in rheumatoid arthritis and is becoming known in other conditions such as arterial pulmonary hypertension.<sup><xref ref-type="bibr" rid="bibr10-0961203312462266">10</xref></sup> Finally, human biological responses to drugs also interfere with TR, ranging from pharmacogenomics-determining different drug metabolism to the induction of neutralizing antibodies to TNF inhibitors (<xref ref-type="table" rid="table2-0961203312462266">Table 2</xref>).
<table-wrap id="table2-0961203312462266" position="float"><label>Table 2</label><caption><p>Determinants of therapeutic resistance (TR)</p></caption>
<graphic alternate-form-of="table2-0961203312462266" xlink:href="10.1177_0961203312462266-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Determinants of therapeutic resistance (TR).</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Related to the patient</td>
</tr>
<tr>
<td>Genomics</td>
</tr>
<tr>
<td>Age, gender, ethnicity</td>
</tr>
<tr>
<td>Related to the disease</td>
</tr>
<tr>
<td>Disease severity</td>
</tr>
<tr>
<td>Different immuno-genetic pathways: A syndrome, not a disease</td>
</tr>
<tr>
<td>Different time of disease for therapeutic intervention</td>
</tr>
<tr>
<td>Related to patient comorbidities and other medication use/interactions</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>TR can relate to one single drug, to several drugs or drug groups or to all available drugs. The latter would correspond to refractory disease.</p>
<p>Refractory disease is a dynamic state and can be redefined as new drugs become available.</p>
<p>Thus, refractory disease should not correspond to “lost causes”: they are only patients for whom the known treatment, at the moment, is not effective. Perhaps one of the best models of these varying outcomes in autoimmune diseases is autologous hematopoietic stem cell transplantation for autoimmune diseases,<sup><xref ref-type="bibr" rid="bibr11-0961203312462266">11</xref></sup> with more than 900 patients enrolled.</p>
<p>In summary, TR does exist but it has not been well defined. TR can scientifically contribute to a better knowledge of potential different pathways for the same clinical entity. Clear attempts to define TR are not happening either in clinical practice or in clinical trials. We are, therefore, losing precious opportunities for progressing in drug research and, ultimately, for improved treatment for patients.</p>
<p>Perhaps a way forward would be to launch a registry of TR and refractory disease with clearly defined criteria as described above.</p>
</body>
<back>
<sec id="sec1-0961203312462266"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec2-0961203312462266"><title>Conflict of interest statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312462266"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>I</given-names></name><name><surname>Faria</surname><given-names>R</given-names></name><name><surname>Vita</surname><given-names>P</given-names></name><name><surname>Vasconcelos</surname><given-names>C</given-names></name></person-group>. <article-title>Systemic sclerosis refractory disease: From the skin to the heart</article-title>. <source>Autoimmun Rev</source> <year>2011</year>; <volume>10</volume>: <fpage>693</fpage>–<lpage>701</lpage>.</citation></ref>
<ref id="bibr2-0961203312462266"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eddou</surname><given-names>H</given-names></name><name><surname>Helissey</surname><given-names>C</given-names></name><name><surname>Konopacki</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Syndrome d’Evans: attention aux diagnostics par excès [Evans syndrome: Be careful of over-diagnosis] [in French]</article-title>. <source>Rev Med Interne</source> <year>2012</year>; <volume>33</volume>: <fpage>155</fpage>–<lpage>158</lpage>.</citation></ref>
<ref id="bibr3-0961203312462266"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnaud</surname><given-names>L</given-names></name><name><surname>Zahr</surname><given-names>N</given-names></name><name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name><name><surname>Amoura</surname><given-names>Z</given-names></name></person-group>. <article-title>The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus</article-title>. <source>Autoimmun Rev</source> <year>2011</year>; <volume>10</volume>: <fpage>674</fpage>–<lpage>678</lpage>.</citation></ref>
<ref id="bibr4-0961203312462266"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginzler</surname><given-names>EM</given-names></name><name><surname>Dooley</surname><given-names>MA</given-names></name><name><surname>Aranow</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>353</volume>: <fpage>2219</fpage>–<lpage>2228</lpage>.</citation></ref>
<ref id="bibr5-0961203312462266"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grootscholten</surname><given-names>C</given-names></name><name><surname>Ligtenberg</surname><given-names>G</given-names></name><name><surname>Hagen</surname><given-names>EC</given-names></name><etal/></person-group>. <article-title>Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial</article-title>. <source>Kidney Int</source> <year>2006</year>; <volume>70</volume>: <fpage>732</fpage>–<lpage>742</lpage>.</citation></ref>
<ref id="bibr6-0961203312462266"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>JA</given-names></name><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Development of classification and response criteria for rheumatic diseases</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>55</volume>: <fpage>348</fpage>–<lpage>352</lpage>.</citation></ref>
<ref id="bibr7-0961203312462266"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>C</given-names></name><name><surname>Jayne</surname><given-names>D</given-names></name><name><surname>Pusey</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>European consensus statement on the terminology used in the management of lupus glomerulonephritis</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation></ref>
<ref id="bibr8-0961203312462266"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YE</given-names></name><name><surname>Korbet</surname><given-names>SM</given-names></name><name><surname>Katz</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Value of a complete or partial remission in severe lupus nephritis</article-title>. <source>Clin J Am Soc Nephrol</source> <year>2008</year>; <volume>3</volume>: <fpage>46</fpage>–<lpage>53</lpage>.</citation></ref>
<ref id="bibr9-0961203312462266"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>PP</given-names></name></person-group>. <article-title>A personalized medicine approach to biologic treatment of rheumatoid arthritis: A preliminary treatment algorithm</article-title>. <source>Rheumatology</source> <year>2012</year>; <volume>51</volume>: <fpage>600</fpage>–<lpage>609</lpage>.</citation></ref>
<ref id="bibr10-0961203312462266"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>EM</given-names></name><name><surname>Manes</surname><given-names>A</given-names></name><name><surname>Celermajer</surname><given-names>DS</given-names></name><name><surname>Galiè</surname><given-names>N</given-names></name></person-group>. <article-title>Early detection of pulmonary vascular disease in pulmonary arterial hypertension: Time to move forward</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>2489</fpage>–<lpage>2498</lpage>.</citation></ref>
<ref id="bibr11-0961203312462266"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farge</surname><given-names>D</given-names></name><name><surname>Labopin</surname><given-names>M</given-names></name><name><surname>Tyndall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases</article-title>. <source>Haematologica</source> <year>2010</year>; <volume>95</volume>: <fpage>284</fpage>–<lpage>292</lpage>.</citation></ref>
</ref-list>
</back>
</article>